CIK 0001384101 · Large accelerated filer
VERACYTE, INC.
Sign in to watch- Ticker
- VCYT
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205455398
- Phone
- (650) 243-6300
- Business address
- 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CALDEROME INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,858,989
- in 9 filings, $2.9M under 10b5-1 plans
Net −$2,858,989. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-04 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 | −1,961 | $50.09 | $98K | 173,280 |
| 2026-06-04 | Stapley Marc Chief Executive Officer | Option exercise 10b5-1 | +138,051 | $36.60 | $5.1M | 578,545 |
| 2026-06-04 | Stapley Marc Chief Executive Officer | Sale 10b5-1 | −138,051 | $50.12 | $6.9M | 440,494 |
| 2026-06-04 | Stapley Marc Chief Executive Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −138,051 | 0 | ||
| 2026-06-02 | Leite John Global Chief Commercial Off | Shares withheld for taxes 10b5-1 | −4,059 | $47.80 | $194K | 146,280 |
| 2026-06-02 | McGuire Annie EVP, General Counsel | Shares withheld for taxes 10b5-1 | −3,292 | $47.80 | $157K | 140,416 |
| 2026-06-02 | Chambers Rebecca Chief Financial Officer | Shares withheld for taxes 10b5-1 | −3,693 | $47.80 | $177K | 176,841 |
| 2026-06-02 | Febbo Phillip G. Chief Scientific & Med Officer | Shares withheld for taxes 10b5-1 | −3,730 | $47.80 | $178K | 149,797 |
| 2026-06-02 | Wygant Jonathan VP, Chief Accounting Officer | Shares withheld for taxes | −1,361 | $47.80 | $65K | 44,073 |
| 2026-06-02 | Stapley Marc Chief Executive Officer | Shares withheld for taxes 10b5-1 | −9,012 | $47.80 | $431K | 440,494 |
| 2026-05-22 | Wygant Jonathan VP, Chief Accounting Officer | Option exercise | +24,000 | $24.80 | $595K | 69,434 |
| 2026-05-22 | Wygant Jonathan VP, Chief Accounting Officer | Sale | −24,000 | $45.40 | $1.1M | 45,434 |
| 2026-05-22 | Wygant Jonathan VP, Chief Accounting Officer | Option exercise · Stock Option (right to buy) | −24,000 | 0 | ||
| 2026-05-20 | EPSTEIN ROBERT S Director | Sale 10b5-1 | −10,000 | $44.01 | $440K | 52,446 |
| 2026-05-06 | McGuire Annie SVP, General Counsel | Sale 10b5-1 | −5,102 | $38.05 | $194K | 148,810 |
| 2026-05-06 | McGuire Annie SVP, General Counsel | Sale 10b5-1 | −5,102 | $40.00 | $204K | 143,708 |
| 2026-04-10 | Haas Kevin Richard Chief Dev and Tech Officer | Grant or award | +44,221 | 44,221 | ||
| 2026-03-06 | Leite John Chief Commercial Officer-CLIA | Grant or award | +36,181 | 143,761 | ||
| 2026-03-06 | Leite John Chief Commercial Officer-CLIA | Grant or award | +6,578 | 150,339 | ||
| 2026-03-06 | McGuire Annie SVP, General Counsel | Grant or award | +32,892 | 127,598 |
Page 3 of 9 · 168 trades